TCM
TCG Crossover Management Portfolio holdings
AUM
$876M
1-Year Return
23.66%
This Quarter Return
-10.83%
1 Year Return
+23.66%
3 Year Return
+996.72%
5 Year Return
–
10 Year Return
–
AUM
$1.02B
AUM Growth
-$157M
(-13%)
Cap. Flow
+$107M
Cap. Flow
% of AUM
10.49%
Top 10 Holdings %
Top 10 Hldgs %
52.04%
Holding
41
New
5
Increased
4
Reduced
2
Closed
3
Top Buys
| 1 |
UPB
Upstream Bio, Inc. Common Stock
UPB
|
$44.9M |
| 2 |
Tango Therapeutics
TNGX
|
$33.2M |
| 3 |
Dianthus Therapeutics
DNTH
|
$32.7M |
| 4 |
Cidara Therapeutics
CDTX
|
$26.1M |
| 5 |
RAPT Therapeutics
RAPT
|
$19.8M |
Top Sells
| 1 |
Edgewise Therapeutics
EWTX
|
$56.4M |
| 2 |
Tarsus Pharmaceuticals
TARS
|
$7.62M |
| 3 |
Keros Therapeutics
KROS
|
$5.21M |
| 4 |
AN2 Therapeutics
ANTX
|
$1.66M |
| 5 |
Adverum Biotechnologies
ADVM
|
$989K |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
CMPS
26
Compass Pathways
CMPS
$493M
| $14.6M | 1.43% |
3,858,000
| – | – |
|
27
Kura Oncology
KURA
$713M
| $12.4M | 1.21% |
1,423,642
| – | – |
|
|
MBX
28
MBX Biosciences, Inc. Common Stock
MBX
$388M
| $12M | 1.17% |
650,000
| – | – |
|
29
Kodiak Sciences
KOD
$556M
| $11.4M | 1.11% |
1,145,538
+137,380
| +14% | +$1.37M |
|
30
Entrada Therapeutics
TRDA
$201M
| $10.1M | 0.99% |
584,955
| – | – |
|
|
31
Keros Therapeutics
KROS
$633M
| $8.71M | 0.85% |
550,000
-329,344
| -37% | -$5.21M |
|
|
32
Adverum Biotechnologies
ADVM
$73.9M
| $8.39M | 0.82% |
1,796,482
-211,857
| -11% | -$989K |
|
33
VistaGen Therapeutics
VTGN
$109M
| $7.9M | 0.77% |
2,676,580
| – | – |
|
|
JBIO
34
Jade Biosciences, Inc. Common Stock
JBIO
$254M
| $5.94M | 0.58% |
64,023
| – | – |
|
35
Nektar Therapeutics
NKTR
$764M
| $3.72M | 0.36% |
266,667
| – | – |
|
36
Avalo Therapeutics
AVTX
$153M
| $3.59M | 0.35% |
483,000
| – | – |
|
37
Ventyx Biosciences
VTYX
$180M
| $692K | 0.07% |
316,195
| – | – |
|
38
Cabaletta Bio
CABA
$155M
| $197K | 0.02% |
86,795
| – | – |
|
|
39
Tarsus Pharmaceuticals
TARS
$2.43B
| – | – |
-231,820
| Closed | -$7.62M |
|
|
40
AN2 Therapeutics
ANTX
$34.4M
| – | – |
-1,555,118
| Closed | -$1.66M |
|
|
41
Edgewise Therapeutics
EWTX
$1.64B
| – | – |
-2,112,984
| Closed | -$56.4M |
|